ASKA Pharmaceutical Holdings ,Ltd. Receivables

The latest receivables for 4886.T is $17B as of June 2026. That compares with $16B in the prior-year period — up 3.1% year over year. Investors often review this figure alongside ASKA Pharmaceutical Holdings ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4886.T's receivables moved from $16B to $17B — a 3.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ASKA Pharmaceutical Holdings ,Ltd.'s operating scale or balance-sheet position.

A receivables figure of $17B for 4886.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4886.T's receivables ($17B), review year-over-year change from $16B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.